Acadia Pharmaceuticals (ACAD) Gross Profit (2016 - 2025)
Acadia Pharmaceuticals (ACAD) has 10 years of Gross Profit data on record, last reported at $257.8 million in Q4 2025.
- For Q4 2025, Gross Profit rose 8.4% year-over-year to $257.8 million; the TTM value through Dec 2025 reached $982.5 million, up 12.16%, while the annual FY2025 figure was $982.5 million, 12.16% up from the prior year.
- Gross Profit reached $257.8 million in Q4 2025 per ACAD's latest filing, roughly flat from $257.0 million in the prior quarter.
- Across five years, Gross Profit topped out at $257.8 million in Q4 2025 and bottomed at $104.4 million in Q1 2021.
- Average Gross Profit over 5 years is $175.8 million, with a median of $170.3 million recorded in 2023.
- Peak YoY movement for Gross Profit: increased 0.51% in 2022, then skyrocketed 58.98% in 2023.
- A 5-year view of Gross Profit shows it stood at $120.0 million in 2021, then rose by 11.72% to $134.1 million in 2022, then skyrocketed by 58.98% to $213.2 million in 2023, then grew by 11.56% to $237.8 million in 2024, then grew by 8.4% to $257.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Gross Profit were $257.8 million in Q4 2025, $257.0 million in Q3 2025, and $243.8 million in Q2 2025.